Secondary Service Connection for Conditions Caused by Your Medications

The rule in plain words

Most veterans know secondary service connection as one condition damaging another. Fewer know that the treatment counts. The regulation says "disability which is proximately due to or the result of a service-connected disease or injury shall be service connected," and once connected, "the secondary condition shall be considered a part of the original condition" (38 CFR 3.310(a)). You take the drug because of the condition. The drug has an effect. The effect is the result of the condition. The direct, secondary, and presumptive post covers how this route fits with the other two.

Worsening counts too. Paragraph (b) covers "Any increase in severity of a nonservice-connected disease or injury" that is due to a service-connected one "and not due to the natural progress" of the first. The Court of Veterans Appeals set that rule in Allen v. Brown in 1995: you are compensated "for the degree of disability (but only that degree) over and above the degree of disability existing prior to the aggravation." The catch is the baseline. The VA "will not concede" aggravation unless the earlier level is "established by medical evidence created before the onset of aggravation," or by the earliest evidence after it. If your reflux was in the chart before the pills, the letter needs that earlier chart to measure from.

The chain the letter has to show

Five links, every one in the record, none in my head.

• The service-connected condition, from the rating decision.
• The medication prescribed for it, with start and stop dates and doses.
• A known effect of that drug, from published studies, with its size and its limits.
• The new condition, diagnosed after the drug started.
• The timing: what the chart showed before the drug and after.

Some chains have an extra link: weight. The VA's General Counsel addressed this in a 2017 precedent opinion that binds raters. Obesity by itself is "not a disease or injury" for VA purposes and cannot be service-connected. But it "may be an 'intermediate step' between a service-connected disability and a current disability that may be service connected on a secondary basis." Raters get three questions: whether the service-connected condition caused the veteran to become obese; whether that obesity "was a substantial factor in causing" the new condition; and whether the new condition "would not have occurred but for" it. A letter that runs through weight answers all three, in order, from your weights. A letter that proves the drug made you heavy and stops there has proved nothing the VA can rate.

NSAIDs for a service-connected back or joint: reflux and gut injury

Ibuprofen, naproxen, meloxicam, diclofenac, taken daily for a service-connected spine or joint. This is the most common medication chain. In a survey of 6,823 French adults, GERD symptoms were present in 27 percent of NSAID users against 19 percent of non-users, and NSAID use was an independent predictor (Ruszniewski and colleagues, 2008). A meta-analysis of 102 studies and 460,984 people put the odds ratio for NSAID or aspirin users at 1.44, an association the authors call modest (Eusebi and colleagues, 2018). Both are cross-sectional: they cannot show the NSAID came first, and pain itself may drive symptom reporting. The letter is strongest when your records show reflux beginning or worsening after the NSAID started. The GERD and GI post covers the rest of that claim.

Lower down, the evidence is stronger and the diagnosis matters more. On blinded capsule endoscopy, small-bowel injury was seen in 71 percent of chronic daily NSAID users against 10 percent of controls (Graham and colleagues, 2005). The honest limit: no study shows NSAIDs cause irritable bowel syndrome directly. The one population study that tested it found IBS tied to analgesic use overall but not to NSAIDs used alone, confounded by other pain (Locke and colleagues, 2000). So I never write "NSAIDs cause IBS." Where the record documents NSAID injury to the bowel first, and the bowel symptoms follow it, the letter argues that chain step by step from the injury, and says plainly that it rests on the record and on mechanism, not on a study of NSAID users. Otherwise the letter argues aggravation of an IBS already there.

Opioids for service-connected pain: breathing in sleep, and the gut

Chronic opioids change breathing during sleep, and the evidence has a dose-response. Sixty chronic opioid patients were matched for age, sex, and body mass index with 60 patients not taking them. The apnea-hypopnea index was higher in the opioid group, 43.5 versus 30.2 events an hour, due to central apneas, 12.8 versus 2.1. Within the opioid group, after controlling for weight, age, and sex, the morphine dose equivalent tracked the apnea indexes, obstructive included, and heavier opioid patients had less severe disturbance, not more (Walker and colleagues, 2007). The authors say the clinical relevance "remains to be established," and the study is retrospective, from one sleep clinic. In 140 chronic pain patients on around-the-clock opioids for at least six months, 75 percent had an abnormal index: 39 percent obstructive, 24 percent central, 8 percent both (Webster and colleagues, 2008). No control group, and the dose relation held only for methadone. The limit that matters: the sleep study has to show central or mixed events. Pure obstructive apnea in a heavy veteran is better argued through weight, as the sleep apnea post explains.

Opioids also act on the gut, and here the label is the argument. In 15 placebo-controlled trials of strong opioids for chronic pain, constipation occurred in 41 percent (Kalso and colleagues, 2004). Narcotic bowel syndrome is "chronic or frequently recurring abdominal pain that worsens with continued or escalating dosages of narcotics" (Grunkemeier and colleagues, 2007). The current Rome V criteria, published in 2026, keep opioid-induced constipation and narcotic bowel syndrome as their own categories, separate from IBS (Corsetti and colleagues, 2026; Fukudo and colleagues, 2026). So the honest claim is one of those disorders secondary to the treatment of your service-connected condition, or aggravation of an IBS you already had. Not "opioids caused my IBS." And no study shows opioids cause GERD itself, so I will not write that they do.

Psychiatric medications for PTSD or depression: weight gain, then sleep apnea

This is the chain the General Counsel opinion was built for, and it is drug-specific. A meta-analysis of 116 studies found that amitriptyline, mirtazapine, and paroxetine "were associated with a greater risk of weight gain." Fluoxetine and bupropion went the other way, with some weight loss. Other compounds had "no transient or negligible effect on body weight in the short term," but the effect "generally became more evident in the long term" (Serretti and Mandelli, 2010). Years on the same prescription is the usual VA fact pattern. Two cautions. Sertraline is not named in that abstract, so a sertraline letter cannot borrow those words. And prazosin, the nightmare medication, is not an antidepressant and is not covered; I have found no published evidence that it causes weight gain. If your only PTSD medication is prazosin, fluoxetine, or bupropion, the weight chain has no published support, and I will tell you so on the screening call.

Antipsychotics used for PTSD sleep have measured numbers. After ten weeks at standard doses, mean gain was 4.15 kilograms for olanzapine and 2.10 for risperidone, against a 0.74 kilogram loss on placebo. Quetiapine, often used off-label for PTSD sleep, had insufficient data (Allison and colleagues, 1999), so a quetiapine letter rests on the class effect plus your own weights.

Then weight to apnea. In a longitudinal sleep cohort, a 10 percent weight gain predicted a 32 percent increase in the apnea-hypopnea index and a six-fold increase in the odds of developing moderate to severe sleep-disordered breathing (Peppard and colleagues, 2000). That is the number a rater can follow from your separation weight to your sleep-study weight. The sleep apnea secondary to PTSD post works this chain in detail.

Corticosteroids and sleep apnea

Prednisone for a service-connected inflammatory condition is a smaller but real pathway. With sleep studies before and after three months of steroid therapy, 15 of 17 patients increased their mean apnea-hypopnea index by 56 percent, from 9.8 to 15.4, and the change was not correlated with weight, neck size, or cumulative dose. Not a weight effect (Berger and colleagues, 2012). The limits are plain: 17 patients, mostly women, three months, and the authors call it preliminary. It shows worsening of existing or borderline disease more than new apnea, so this is usually an aggravation theory, with the baseline problem that brings. No study of steroid-treated Crohn's or other inflammatory bowel disease patients and apnea has been located. A letter should say that.

What does not work

"My medication list is long, so something must be secondary." The VA does not rate a medication list. The letter needs one drug, one effect with a citation, the start date, and the diagnosis date. Without those four, I have a hunch, not an opinion.

A letter that answers only causation. In El-Amin v. Shinseki in 2013, the VA examiner said the condition was not "caused" by the service-connected one. The Court held that this "does not rule out the possibility that it was also aggravated to some degree," and that the Board was wrong to rely on it. That cuts both ways. If the VA's examiner addressed only causation, the opinion is incomplete when aggravation is in play. And my own letter gives two separate answers, caused and aggravated, each with its own reasoning. With medication chains the facts almost always raise aggravation.

A letter that claims an effect the evidence does not support. Fluoxetine and weight gain. Prazosin and weight gain. NSAIDs causing IBS with no documented bowel injury in between. Opioids and GERD. Each is a gift to the examiner.

The examiner's counterargument, and the honest answer

The examiner will say the new condition is common and you have the usual risk factors. For reflux that is true: prevalence is 18.1 to 27.8 percent in North America (El-Serag and colleagues, 2014), and age over 50, smoking, and obesity each raise the odds (Eusebi and colleagues, 2018). For sleep apnea, 24 percent of middle-aged men had it in the foundational cohort, with male sex and obesity strongly associated (Young and colleagues, 1993). A letter that argues with those numbers loses. A letter that concedes them and makes two points does not. A base rate describes a population; it does not say when your condition began or what drove it. And timing and dose are the evidence the examiner usually skipped: no reflux, then a daily NSAID, then reflux; a sleep study after the morphine equivalent went up; a weight curve that bends the month the mirtazapine started. With that in the record, "it would have happened anyway" is an assertion. Where the record shows the condition before the drug, causation is out, I say so, and the letter turns to aggravation with the baseline the regulation requires.

What I need from you

• Pharmacy records with start and stop dates. VA Blue Button medication history or pharmacy printouts. Doses matter most for opioids.
• The rating decisions for the condition the drug treats, and any decision on the new condition.
• Weights over time, where weight is the link. Separation physical, VA vitals, anything with a date and a number.
• The diagnosis records for the new condition. The full sleep study, the endoscopy report, the GI note that named it.
• Every C&P opinion on the new condition. If one says "not caused by," I need to read what it did and did not address.

Send what you have. If not sure, the $395 records analysis tells you what is missing before you pay for a letter.

Who should write it

This is pharmacology and physiology: what a drug does, at what dose, over what time, and whether your chart shows it. The right author is a qualified clinician, one whose training covers the question, who reviews the whole record and reasons from the published evidence, whatever the letters after the name, and the letter should say who wrote it, what was reviewed, and where the evidence is thin. I write these. One boundary: when the question is whether the psychiatric diagnosis is correct, or whether a psychiatric condition is service-connected at all, that is a psychiatry question, and I refer those veterans to a board-certified psychiatrist, and say so on the screening call. Once the condition is rated and the question is what its medication did to your weight or your sleep, I take it.

Getting a nexus letter for a condition caused by your medication

Who writes it here. I am a board-certified emergency physician, and I write these opinions myself, from your pharmacy records and your chart, with the studies above cited by name in the letter. If the chain is not in your records, the analysis says so and you do not pay for a letter.

What it costs. The screening call is free, 15 minutes with me. A standard letter is $995 with the full records review included, or $395 for a records analysis first and $600 for the letter after it. If the VA has already denied this condition, you are rebutting an adverse C&P opinion, or the claim is at appeal, it is $1,495. Each additional condition on the same records is $500. No contingency, no percentage of back pay, and the price is confirmed in writing on the call before you pay anything.

How to start. Request the free screening call. Tell me the service-connected condition, the drug, and the new diagnosis, and I will tell you honestly whether the evidence supports the chain. Records come later, through a secure link, never by email. No outcome is guaranteed. If the records do not support the claim, I will tell you that instead of writing the letter.

Studies and authorities referred to in this post

38 C.F.R. § 3.310, Disabilities that are proximately due to, or aggravated by, service-connected disease or injury (2025 ed.).
Allen v. Brown, 7 Vet. App. 439 (1995) (en banc).
El-Amin v. Shinseki, 26 Vet. App. 136 (2013).
VAOPGCPREC 1-2017, Service Connection Based on Obesity (VA Office of General Counsel, Jan. 6, 2017).
Ruszniewski P, Soufflet C, Barthélémy P. Nonsteroidal anti-inflammatory drug use as a risk factor for gastro-oesophageal reflux disease: an observational study. Aliment Pharmacol Ther. 2008;28(9):1134-1139. PMID 18671778.
Eusebi LH, et al. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018;67(3):430-440. PMID 28232473.
Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol. 2005;3(1):55-59. PMID 15645405.
Locke GR 3rd, et al. Risk factors for irritable bowel syndrome: role of analgesics and food sensitivities. Am J Gastroenterol. 2000;95(1):157-165. PMID 10638576.
Walker JM, et al. Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing. J Clin Sleep Med. 2007;3(5):455-461. PMID 17803007.
Webster LR, Choi Y, Desai H, Webster L, Grant BJ. Sleep-disordered breathing and chronic opioid therapy. Pain Med. 2008;9(4):425-432. PMID 18489633.
Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112(3):372-380. PMID 15561393.
Grunkemeier DM, Cassara JE, Dalton CB, Drossman DA. The narcotic bowel syndrome: clinical features, pathophysiology, and management. Clin Gastroenterol Hepatol. 2007;5(10):1126-1139. PMID 17916540.
Corsetti M, et al. Bowel Disorders. Gastroenterology. 2026;170(6):1261-1282. PMID 41713703.
Fukudo S, et al. Centrally Mediated Disorders of Gastrointestinal Pain. Gastroenterology. 2026;170(6):1283-1302. PMID 41692277.
Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010;71(10):1259-1272. PMID 21062615.
Allison DB, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686-1696. PMID 10553730.
Peppard PE, Young T, Palta M, Dempsey J, Skatrud J. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA. 2000;284(23):3015-3021. PMID 11122588.
Berger G, Hardak E, Shaham B, Avitan E, Yigla M. Preliminary prospective explanatory observation on the impact of 3-month steroid therapy on the objective measures of sleep-disordered breathing. Sleep Breath. 2012;16(2):549-553. PMID 21755279.
El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871-880. PMID 23853213.
Young T, et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993;328(17):1230-1235. PMID 8464434.

This post is general information about VA claims, not medical advice about your condition or legal advice about your claim. Every opinion I write rests on the veteran's own records.

Related. Sleep apnea secondary to PTSD, Secondary conditions from a service-connected back, The C&P examiner said no: what a rebuttal opinion has to do.